Pharmacogenomics Certificate Program
Share |
   

Pharmacogenomics Certificate Program

Activity Type: Practice-based

Target Audience: Pharmacists, Residents and Students
Activity Fee:

Pharmacists:                 $450 CSHP members | $800 CSHP non-members 

Pharmacy Students:  $200 CSHP members | $250 CSHP non-members
Duration: 15 contact hours: 7 hours online/8 hours live (No partial credit given)
Release Date:
 October 25, 2017
Expiration Date: October 25, 2020
ACPE Activity Numbers(s): 0126-0000-17-589-B01-P

 


Note: You must log in to your CSHP account to purchase the program and each time you access this certificate program



 

 

Program Overview

This program is designed specifically for health-system pharmacists to provide them with the knowledge of genetic factors that influence drug disposition, response, and adverse effects. Program participants will gain the practical clinical skills necessary to apply precision medicine at their own practice settings.

Topics Covered:

  •  Pharmacogenomics fundamentals
  •  Clinical implementation issues and educational resources
  • Drug-induced hypersensitivity reactions
  • Psychiatry/Pain
  • Cardiology
  • Oncology

Special Features:
The first 50 registrants who register by August 30, will receive a free genetics test kit and report ($250 value) to be included as part of the live session.  The genetics test kit includes 21 drug-specific alleles that are clinically used (e.g., COMT, CYP2C19, CYP2D6, CYP3A4, MTHFR, SLCO1B1, VKORC1).  Attendees must register by August 30, 2018 to receive a test kit. Those who register after the deadline will use a mock test report during the live session.

Live Program:

  • The live session will take place at Seminar 2018 on October 4, 2018, 8:00am – 5:00pm at the beautiful Sheraton San Diego Hotel and Marina. 
  •  The online content will be expanded upon and practice-based patient cases will be discussed through an interactive forum.
  • Personal pharmacogenetic test and report. Participants will have an opportunity to review and interpret their own personal genetics report if they register by August 30. Those participants who do not register by August 30th will use a mock test report for instructional purposes during the live session.

Online Modules and Objectives

Module 1: Pharmacogenomics Fundamentals

  • Define pharmacogenomics
  • Describe the clinical potential of pharmacogenomics.
  • Explain basic pharmacogenomics nomenclature.
  • List examples of clinical applications of pharmacogenomics.

 Module 2: Clinical Implementation of Pharmacogenomics 

  • Describe challenges with clinical implementation of pharmacogenomics.
  •  Identify and use available pharmacogenomics resources.
  • List factors for integrating pharmacogenomics into clinical practice.
  • Describe ethical, legal, social implications related to pharmacogenomics implementation in clinical practice.

Module 3: Psychiatry and Pain

  • List the genotype variants involved in psychotropicsand opioids efficacy and toxicity.
  •  Describe the various applications of pharmacogenomics in psychiatric pharmacy practice and pain management.
  • Discuss the current recommendations for pharmacogenomic testing for psychotropics and opioids.

Module 4: Drug-Induced Hypersensitivity Reactions

  •  List the genotype variants associated with drug-induced hypersensitivity reactions.
  •  Discuss the current recommendations for pharmacogenomic testing for commonly used drugs associated with hypersensitivity reactions.
  • Explain how the identification of specific polymorphisms of certain drugs translate into clinical application.

Module 5:Oncology

  • Describe how the germline genome affects drug exposure and/or toxicity in oncology patients.
  • Discuss the current development of pharmacogenomics associated with the clinical practice in oncology.
  • Describe the various applications of pharmacogenomics in oncology clinical practice.

Module 6: Cardiology

  • List the genotype variants involved in the efficacy of antiplatelet, anticoagulant and statin agents.
  • Discuss the current recommendations for pharmacogenomic testing for antiplatelet and anticoagulant agents.
  • Describe challenges in clinical implementation of pharmacogenomic testing for antiplatelet and anticoagulant agents.

Faculty

Mary A. Gutierrez, PharmD, BCPP
Professor
Department of Pharmacy Practice
Chapman University School of Pharmacy

Jerika T. Lam, PharmD, AAHIVP, FCSHP
Associate Professor
Department of Pharmacy Practice
Chapman University School of Pharmacy

Samit Shah, PhD, MBA, RPh
Associate Dean of Academic Affairs
Sidney J. Weinberg Professor
Keck Graduate Institute



Javad Tafreshi, Pharm.D., BCPS-AQ Cardiology, F.A.H.A., APh
Professor and Associate Dean of Academic Affairs
College of Pharmacy
Marshall B. Ketchum University

Sun (Coco) Yang, B.Pharm, Ph.D, BCPPS, APh.
Assistant Professor
Department of Pharmacy Practice
Chapman University School of Pharmacy

Shaun Opie, PhD (live session guest speaker)
Chief Scientific Officer
Universal DX Labs

Methods and CE Requirements

Participants will be provided a session code for the entire certificate program at the live event. All online home studies must be taken and passed to attend the live portion.

NOTE: If a participant fails to complete any portion of the program, no refund will be given.Transfers to a later live session are not allowed.


Disclosures

In accordance with the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, CSHP require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speaker’s bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

In keeping with this requirement, CSHP asks that all faculty, advisory board members, planning committee members, content development consultants, and staff complete a disclosure form for each program in which they are involved. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

 




The California Society of Health-System Pharmacists is an accredited provider of continuing pharmacy education by the Accreditation Council for Pharmacy Education. 

Contacts

California Society of Health-System Pharmacists
1314 H Street, Suite 200
Sacramento, CA 95814
Office: (916) 447-1033
Fax: (916) 447-2396
Email: info@cshp.org
Hours: M-F 8:00am – 5:00pm

Connect